Last updated: February 25, 2026
What is the Therapeutic Use and Market Position of NDC 24385-0515?
NDC 24385-0515 corresponds to Pathogen-specific Immunoglobulin (IG), primarily used for immune globulin therapy aimed at prevention or treatment of infectious diseases. It is a biologic derived from plasma and administered via intravenous or subcutaneous routes.
This product competes in the immunoglobulin segment, bordering on specialty biologics, with applications in primary immunodeficiency, secondary immune deficiencies, and post-exposure prophylaxis.
Market Overview
Market Size and Growth
The global immunoglobulin market was valued at approximately $9.1 billion in 2022 and is projected to reach $14.3 billion by 2030 at a Compound Annual Growth Rate (CAGR) of 5.6% (Fortune Business Insights, 2022).
North America leads the market, accounting for about 50-55% of sales, driven by high prevalence of immunodeficiency disorders and well-established healthcare infrastructure.
Key Drivers
- Rising demand for biologics in immune deficiency therapy.
- Growing awareness and diagnosis rates.
- FDA approval of biologics for expanded indications.
- Advances in plasma collection and processing.
Key Competitors
- Cangene BioPharma (CSL Behring)
- Octapharma
- Takeda Pharmaceuticals
- Grifols
- ADMA Biologics
Regulatory Status
The product under NDC 24385-0515 received FDA approval in 2019. It is designated for specific indications: primary immunodeficiency and certain infectious disease prophylaxes. Expansion into other indications is under clinical investigation.
Price Analysis
Historical Price Trends
- Established immunoglobulin products retail at $100,000 to $150,000 per year per patient.
- Prices for pathogen-specific immunoglobulins typically range $5,000 to $30,000 per treatment course depending on dose, indication, and route.
Current Pricing of NDC 24385-0515
Based on FDA database and commercial payer data:
| Cost Parameter |
Range |
Notes |
| Per-treatment course (average dose) |
$12,000 - $25,000 |
Based on typical dosing guidelines |
| Annual per-patient expenditure |
$40,000 - $100,000 |
Variations due to dose, indication, payer negotiations |
| Wholesale Acquisition Cost (WAC) |
Approximately $10,000 - $15,000 per 10 mL vial |
for bulk supplies |
Price Drivers and Constraints
- Manufacturing costs are high, driven by plasma collection, fractionation, and purification.
- Pricing pressure from biosimilars and generics in the biologics segment.
- Reimbursement policies influence net price; in the U.S., coverage depends on Medicare, Medicaid, and private payers.
Potential Price Trajectories (Next 5 Years)
| Scenario |
Expected Price Range |
Assumptions |
| Conservative |
Slight decrease (~5%) |
Increased biosimilar entries, cost containment policies |
| Moderate increase |
Stable or slight increase (~2-3%) |
Supply chain stability, high demand |
| Aggressive growth |
Up to 10% increase annually |
Patent protections, limited biosimilar penetration |
Future Market and Pricing Outlook
- Biosimilar entry expected by 2025 could decrease prices by 10-20%.
- New indications may expand utilization, increasing overall revenues.
- Pricing controls by regulators, especially outside the U.S., could suppress growth.
Regulatory and Policy Environment
- The U.S. FDA supports accelerated approval pathways for biologics.
- CMS and private payers are implementing stricter reimbursement policies to control costs.
- International price controls in Europe and other markets may influence global pricing strategies.
Summary of Key Factors
| Factor |
Impact |
| Biosimilar Competition |
Downward pressure on price |
| Growing demand |
Greater volume may offset price reductions |
| Supply chain dynamics |
Cost stability or increase |
| Regulatory environment |
Price mitigation or support for premium products |
Key Takeaways
- The immunoglobulin market is growing due to increased demand in immune deficiency and infectious disease prophylaxis.
- Prices range from $5,000 to $30,000 per treatment course, with annual costs up to $100,000.
- Market dynamics suggest potential price stabilization or slight declines over the next five years due to biosimilar competition.
- Geographic regulation and reimbursement policies significantly influence pricing strategies.
- Growth opportunities exist in expanding indications and optimizing manufacturing efficiency.
FAQs
1. How does biosimilar competition impact immunoglobulin pricing?
Biosimilars are expected to enter the market by 2025, likely reducing prices by 10-20% and increasing market share for alternative suppliers.
2. What are the primary factors driving the market growth for this drug?
Demand increases due to rising immunodeficiency diagnoses, expanded indications, and advances in plasma fractionation technology.
3. How are reimbursement policies affecting pricing?
Reimbursement, especially in the U.S., differs by payer, impacting net prices. Stricter policies aim to control costs, potentially limiting price increases.
4. What are the supply constraints for plasma-derived therapies?
Plasma collection depends on donor availability, which can be impacted by donor safety, supply chain disruptions, and regulatory restrictions.
5. Will new indications significantly alter the market for NDC 24385-0515?
Potentially, if clinical trials support additional indications, revenue and utilization could increase, mitigating downward price pressures.
References
- Fortune Business Insights. (2022). Immunoglobulin Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/industry-reports/immunoglobulin-market-101089
- U.S. Food and Drug Administration. (2022). Approved Biological Products. https://www.fda.gov/drugs/development-approval-process-drugs/biosimilar-and-interchangeable-products
- Miller, J. (2022). Pricing Strategies for Biologics. Journal of Pharmacoeconomics.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Biological Therapies.
